Holen Sie sich die Stockscreener-App
24.66
0.96%
-0.24
Handel nachbörslich:
24.66
Schlusskurs vom Vortag:
$24.90
Offen:
$24.71
24-Stunden-Volumen:
1.13M
Relative Volume:
3.09
Marktkapitalisierung:
$2.31B
Einnahmen:
$14.09M
Nettoeinkommen (Verlust:
$-176.94M
KGV:
-9.2526
EPS:
-2.6652
Netto-Cashflow:
$-141.24M
1W Leistung:
+0.28%
1M Leistung:
+28.04%
6M Leistung:
+22.75%
1J Leistung:
+160.95%
1-Tages-Spanne:
$24.10
$25.32
1-Wochen-Bereich:
$24.10
$25.32
52-Wochen-Spanne:
$8.90
$26.35
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Firmenname
Newamsterdam Pharma Company Nv
Sektor
Branche
Telefon
35 206 2971
Adresse
GOOIMEER 2-35, NARRDEN
Vergleichen Sie NAMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| NAMS | 24.66 | 2.31B | 14.09M | -176.94M | -141.24M | -2.6652 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-18 | Eingeleitet | Guggenheim | Buy |
| 2024-01-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-10-30 | Eingeleitet | RBC Capital Mkts | Outperform |
Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 - The Manila Times
RA Capital Management, L.P. Expands Stake in NewAmsterdam Pharma Co NV - GuruFocus.com
GSA Capital Partners LLP Has $1.10 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) surges 13%; private equity firms who own 46% shares profited along with institutions - Simply Wall St
When the Price of (NAMS) Talks, People Listen - Stock Traders Daily
Is NewAmsterdam Pharma (NAMS) Top Performing European Stock Heading into 2025? - Insider Monkey
10 Top Performing European Stocks Heading into 2025 - Insider Monkey
Lisanti Capital Growth LLC Invests $700,000 in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NewAmsterdam Pharma Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Q4 EPS Forecast for NewAmsterdam Pharma Reduced by Analyst - Defense World
William Blair Issues Pessimistic Forecast for NAMS Earnings - MarketBeat
Leerink Partnrs Has Bullish Outlook for NAMS FY2024 Earnings - MarketBeat
Equities Analysts Offer Predictions for NAMS FY2024 Earnings - Defense World
Leerink Partnrs Has Strong Estimate for NAMS FY2028 Earnings - Defense World
Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $33.80 - Defense World
(NAMSW) Proactive Strategies - Stock Traders Daily
What is Leerink Partnrs' Forecast for NAMS FY2028 Earnings? - MarketBeat
NewAmsterdam Pharma Reports Strong Q3 and Trial Progress - TipRanks
NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
What 4 Analyst Ratings Have To Say About NewAmsterdam Pharma - Benzinga
Newamsterdam Pharma Faces Compliance Cost Surge as Emerging Growth Status Ends - TipRanks
NewAmsterdam Pharma (NASDAQ:NAMS) Receives $33.80 Consensus PT from Analysts - MarketBeat
NewAmsterdam Pharma Revenue Soars 900%, Reports Strong Q3 Results Ahead of Key Trial Data | NAMS Stock News - StockTitan
abrdn plc Purchases 53,060 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
(NAMS) Technical Pivots with Risk Controls - Stock Traders Daily
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November - The Manila Times
Needham Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation - MSN
NewAmsterdam Pharma to Restate Prior Financials - Investing.com India
NewAmsterdam Pharma to Restate Prior Financials By Investing.com - Investing.com Australia
(NAMSW) Trading Report - Stock Traders Daily
NewAmsterdam Pharma Breaks Above 200-Day Moving AverageBullish for NAMS - Nasdaq
Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) Target Price at $33.80 - MarketBeat
NewAmsterdam Pharma Company N.V. (NAMS) Price Target Increased by 8.93% to 31.11 - MSN
Marshall Wace LLP Decreases Stake in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
When the Price of (NAMSW) Talks, People Listen - Stock Traders Daily
Millennium Management LLC Has $22.39 Million Stock Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies - Seeking Alpha
NewAmsterdam Pharma executive sells shares worth $707,400 - Investing.com India
NewAmsterdam Pharma executive sells shares worth $707,400 By Investing.com - Investing.com UK
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down to $16.60 - MarketBeat
NewAmsterdam Pharma Company NV (NAMS) rating initates by TD Cowen - Knox Daily
Does NewAmsterdam Pharma Company NV (NAMS) offer a good opportunity for investors? - SETE News
Newamsterdam Pharma exec buys $17,332 in company stock By Investing.com - Investing.com Australia
Newamsterdam Pharma exec buys $17,332 in company stock - Investing.com India
NewAmsterdam Pharma (NASDAQ:NAMS) Sees Strong Trading Volume - MarketBeat
TD Cowen Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation - MSN
Deerfield Management Company L.P. Series C Has $16.70 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
Affinity Asset Advisors LLC Boosts Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
Investment opportunity in NewAmsterdam Pharma stock as anticipation builds for BROADWAY results By Investing.com - Investing.com
NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Overweight" Rating from Piper Sandler - MarketBeat
Finanzdaten der Newamsterdam Pharma Company Nv-Aktie (NAMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):